Skip to main content

Table 3 Hematologic adverse events

From: Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

 

Any, N (%)

Grade ≥ 3, N (%)

DARA-DCEP cycle 1 (N = 31)

  

 Thrombocytopenia

8 (25.8)

5 (16.1)

 Lymphopenia

7 (22.6)

2 (6.5)

 Neutropenia

6 (19.4)

4 (12.9)

 Documented infection

2 (6.5)

NA

DARA-DCEP cycle 2 (N = 29)

  

 Thrombocytopenia

8 (27.6)

5 (17.2)

 Lymphopenia

5 (17.2)

4 (13.8)

 Neutropenia

6 (20.7)

4 (13.8)

 Documented infection

6 (20.7)

NA

DARA-DCEP cycle 3 (N = 25)

  

 Thrombocytopenia

12 (48.0)

9 (36.0)

 Lymphopenia

9 (36.0)

5 (20.0)

 Neutropenia

6 (24.0)

2 (8.0)

 Documented infection

2 (8.0)

NA

DARA maintenance cycle 1 (N = 19)

  

 Thrombocytopenia

4 (21.1)

4 (21.1)

 Lymphopenia

2 (10.5)

1 (5.3)

 Neutropenia

0

0

 Documented infection

1 (5.3)

NA

DARA maintenance cycle 2 (N = 14)

  

 Thrombocytopenia

0

0

 Lymphopenia

1 (7.1)

1 (7.1)

 Neutropenia

0

0

 Documented infection

0

NA

DARA maintenance cycle 3 (N = 11)

  

 Thrombocytopenia

1 (9.1)

1 (9.1)

 Lymphopenia

1 (9.1)

1 (9.1)

 Neutropenia

1 (9.1)

1 (9.1)

 Documented infection

0

NA

DARA maintenance cycle 4 (N = 9)

  

 Thrombocytopenia

0

0

 Lymphopenia

0

0

 Neutropenia

2 (22.2)

0

 Documented infection

0

NA

DARA maintenance cycle 5 (N = 7)

  

 Thrombocytopenia

1 (14.3)

0

 Lymphopenia

0

0

 Neutropenia

0

0

 Documented infection

0

NA

  1. NA not applicable